ArticleMolecular medicine (Cambridge, Mass.)2026
DCLK1 mediates airway epithelial barrier disruption through NF-κB activation in severe asthma.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSevere asthma is characterized by epithelial barrier dysfunction, airway remodeling, and chronic inflammation. Doublecortin-like kinase 1 (DCLK1), a kinase initially identified as a cancer stem cell marker, has been linked to NF-κB-mediated inflammatory responses. However, its role in TGF-β-induced epithelial barrier disruption in severe asthma remains unclear.
methodsThe expression of DCLK1 and junctional proteins was examined in bronchial epithelial tissue biopsies and air-liquid interface (ALI) cultures derived from patients with severe asthma and healthy controls. The role of DCLK1 was investigated in vitro using TGF-β-treated BEAS-2B cells and in vivo using ovalbumin (OVA)- and house dust mite (HDM)-induced murine asthma models. Global DCLK1 knockout mice were employed to assess epithelial integrity, airway remodeling, and inflammatory responses in murine asthma.
resultsDCLK1 expression was increased in bronchial epithelial cells from patients with severe asthma. DCLK1 siRNA reversed TGF-β-induced epithelial dysfunction by restoring E-cadherin expression and reducing fibronectin and N-cadherin levels in BEAS-2B cells. Moreover, DCLK1 silencing improved epithelial barrier function, as evidenced by increased transepithelial electrical resistance (TEER) and E-cadherin expression. Mechanistically, DCLK1 mediates TGF-β-induced EMT via activation of the NF-κB signaling pathway. DCLK1 knockout mice exhibited improved lung function and reduced airway inflammatory cell infiltration compared with wild-type mice under both OVA and HDM exposure.
conclusionsDCLK1 promotes airway epithelial barrier dysfunction in severe asthma through NF-κB activation. Targeting DCLK1 may represent a novel therapeutic strategy to restore epithelial integrity in severe asthma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.